ភាគហ៊ុន AbbVie បំបែកការបោះជំហានរបស់ខ្លួន ខណៈដែលនាយកប្រតិបត្តិដ៏សំខាន់ចាកចេញសម្រាប់ភាពល្បីល្បាញ

AbbVie stock crumbled Wednesday after the company announced President and Vice Chairman Michael Severino will depart at the end of May.

X

Severino is heading to Flagship Pioneering, the biotech creator behind big names like Moderna (MRNA), and smaller players ព្យាបាលរោគដេលី (DNLI) និង Seres Therapeutics (MRCB) — to name a few. He will become a partner chief executive at Flagship and will head up one of its companies.

He’s leaving AbbVie after eight years. In his role, he’s been responsible for research and development, and the corporate strategy office. Severino informed AbbVie of his plans on April 8, according to a Securities and Exchange Commission filing.

នៅ​លើ ផ្សារភាគហ៊ុនថ្ងៃនេះ, AbbVie stock toppled 4.2% to 158.95.

AbbVie Stock Dives As Severino Exits

As a CEO-partner, Severino will help Flagship “create and develop groundbreaking innovations in human health,” the company said in a news release.

Severino has worked in drug development for more than two decades. Prior to AbbVie, he worked at Amgen (អេអឹមជីអិន) និង Merck (MRK).

“I am thrilled to take on this role and partner with the high-caliber team of world-class scientists, technologists and business executives assembled by Flagship Pioneering,” Severino said in a written statement. “I look forward to applying my experience across all phases of drug discovery, development and commercialization at Flagship, to help make an important difference for patients.”

During Severino’s tenure, AbbVie added Skyrizi and Rinvoq, two new immunology drugs that could help stanch an expected decline in revenue as Humira — the world’s bestselling drug — begins facing cheaper biosimilar rivals in the U.S. Biosimilars to Humira are likely to shake AbbVie stock.

AbbVie also won Food and Drug Administration approval last year for a migraine prevention pill known as Qulipta, a potential rival to ឱសថ Biohaven'(ប៊ីអេជ។ អិន) Nurtec.

The news of Severino’s departure also comes as AbbVie announces the 20-year anniversary of the first FDA approval for Botox. At the time, it was approved as a cosmetic treatment for wrinkles. Now, it’s also used to treat migraines, excessive sweating and other conditions.

Shares Hit Their Stride This Year

AbbVie stock has been on a run this year, rising nearly 30% to a record of 175.91 on April 8.

Severino’s looming exit sent shares tumbling, but the pharma stock still remains well above its 50- ថ្ងៃ និង 200- ថ្ងៃ moving averages.

Bullishly, AbbVie stock also has a ការវាយតម្លៃសមាសធាតុ of 95. This puts shares in the top 5% of all stocks in terms of fundamental and technical measures, according to អេឌីឌីឌីជីថល។ នេះ ការវាយតម្លៃកម្លាំងទាក់ទង of 96 means AbbVie stock trades in the leading 4% in terms of 12-month performance.

តាម Allison Gatlin នៅលើ Twitter នៅ @IBD_AGatlin.

អ្នកអាចចូលចិត្តបានផងដែរ៖

Myovant Sciences Collapses As FDA Holdup Snags Its Blockbuster Potential

Biotech Feeding Spree As GSK, Halozyme Announce Nearly $3 Billion In Deals

ចង់បានការយល់ដឹងរបស់ IBD បន្ថែមទេ? ជាវដើម្បីផតខាស់វិនិយោគរបស់យើង!

ទទួលបានគំនិតភាគហ៊ុនពីអ្នកជំនាញ IBD រៀងរាល់ព្រឹកមុនពេលបើក

អាយ។ អេ។ អេ។ អាយ។ អេសនៃថ្ងៃ៖ សូមមើលរបៀបស្វែងរកតាមដាននិងទិញភាគហ៊ុនដែលល្អបំផុត